Helicobacter pylori promotes colorectal carcinogenesis by deregulating intestinal immunity and inducing a mucus-degrading microbiota signature

4

5 Anna Ralser¹, Alisa Dietl¹, Sebastian Jarosch¹, Veronika Engelsberger¹,

6 Andreas Wanisch¹, Klaus Peter Janssen², Michael Vieth³, Michael Quante^{4,5},

7 Dirk Haller^{6,7}, Dirk H. Busch^{1,9}, Li Deng⁸, Raquel Mejías-Luque^{1,9}†, Markus

8 Gerhard^{1,9}†*

9 Affiliations:

- ¹ Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, Munich, 81675,
 Germany.
- ² Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Surgery, Munich,
 81675, Germany.
- ³ Institute of Pathology, Friedrich-Alexander University Erlangen-Nuremberg, Klinikum Bayreuth, Bayreuth, 95445,
 Germany.
- ⁴ Klinik für Innere Medizin II, Gastrointestinale Onkologie, Universitätsklinikum Freiburg, Freiburg, 79106,
 Germany.
- 18 ⁵ Klinik und Poliklinik für Innere Medizin II, Technical University of Munich, Munich, 81675, Germany.
- ⁶ Chair of Nutrition and Immunology, Technical University of Munich, Freising-Weihenstephan, 85354, Germany.
- ⁷ ZIEL Institute for Food & Health, Technical University of Munich, Munich, 80333, Germany

⁸ Institute of Virology, School of Medicine, Helmholtz Center Munich, Technical University of Munich, Garching,
 85748, Germany.

- ⁹ German Center for Infection Research (DZIF), Munich Partner Site, Munich, 81675, Germany.
- 24
- 25 *Corresponding author. Email: markus.gerhard@tum.de
- 26 † These authors contributed equally to this work
- 27

28

29 ABSTRACT

30 OBJECTIVE

H. pylori infection is the most prevalent bacterial infection worldwide. Besides being the most
important risk factor for gastric cancer development, epidemiological data show that infected
individuals harbor a nearly two-fold increased risk to develop colorectal cancer (CRC).
However, a direct causal and functional connection between *H. pylori* infection and colon
cancer is lacking.

36 DESIGN

We infected two *Apc*-mutant mouse models and C57BL/6 mice with *H. pylori* and conducted a comprehensive analysis of *H. pylori*-induced changes in intestinal immune responses and epithelial signatures via flow cytometry, chip cytometry, immunohistochemistry and single cell RNA sequencing. Microbial signatures were characterized and evaluated in germ-free mice and via stool transfer experiments.

42 RESULTS

43 H. pylori infection accelerated tumor development in Apc-mutant mice. We identified a 44 unique *H. pylori*-driven immune alteration signature characterized by a reduction in regulatory T-cells and proinflammatory T-cells. Furthermore, in the intestinal and colonic 45 46 epithelium, H. pylori induced pro-carcinogenic STAT3 signaling and a loss of goblet cells, 47 changes that have been shown to contribute - in combination with pro-inflammatory and 48 mucus degrading microbial signatures - to tumor development. Similar immune and epithelial 49 alterations were found in human colon biopsies from H. pylori-infected patients. Housing of 50 Apc-mutant mice under germ-free conditions ameliorated, and early antibiotic eradication of 51 *H. pylori* infection normalized the tumor incidence to the level of uninfected controls.

52 CONCLUSIONS

53 Our studies provide evidence that *H. pylori* infection is a strong causal promoter of colorectal 54 carcinogenesis. Therefore, implementation of *H. pylori* status into preventive measures of 55 CRC should be considered.

56

57 **INTRODUCTION**

58 Helicobacter pylori infection affects more than half of the world's population and it is a main 59 risk factor for gastric cancer. H. pylori induces a number of alterations in the gastric mucosa 60 that together result in neoplastic transformation of the epithelium. Thus, H. pylori infection 61 first triggers a complex plethora of immune cascades, directed towards H. pylori and 62 orchestrated by the bacterium itself, which originate from priming at the Peyer's Patches and 63 the mesenteric lymph nodes of the small intestine (1, 2). The major pro-inflammatory 64 response towards H. pylori consists of a mixed Th1 and Th17 response (1), and is to a large 65 extent related to the presence and activity of a type 4 secretion system (T4SS) (3), which 66 mediates translocation of the oncogenic and highly immunogenic protein CagA into gastric 67 epithelial cells (4). This leads to chronic inflammation and results in the activation of pro-68 inflammatory signaling pathways such as activating Nuclear Factor-κB (NF-κB) and signal 69 transducer and activator of transcription 3 (STAT3) signaling, which are major drivers of H. pylori induced gastric carcinogenesis (5). However, H. pylori has evolved counter 70 71 mechanisms in order to establish and maintain chronic infection, for example by 72 reprogramming dendritic cells (DCs) to induce regulatory T-cells (Treg) (6, 7), which not only 73 counterbalance the local pro-inflammatory response in the stomach (8), but are also involved 74 in protection from allergic asthma (9). Interestingly, this tolerogenic reprogramming of DCs is 75 partially mediated by CagA, via activation of STAT3 (7). Finally, alterations in gastric 76 microbiota are observed upon infection, which seem to contribute to the deleterious events 77 leading to gastric cancer following H. pylori infection (10). This idea is supported by studies 78 using animal models as the insulin-gastrin (INS-GAS) mice, which showed more severe 79 gastric pathology and early development of neoplasia when colonized with H. pylori and 80 carrying normal commensal microbiota compared to germ free INS-GAS mice infected with 81 the bacterium (11).

Although *H. pylori* infection is limited to the stomach, accumulating epidemiological data indicate an association between *H. pylori* infection and different extra-gastric diseases (12). Among those, a higher risk of colorectal cancer has been reported to be associated with *H. pylori* infection status (13). However, the mechanisms that could explain this increased risk have not been elucidated.

In our study, we identify *H. pylori*-specific alterations in gut homeostasis that contribute to colorectal carcinogenesis in mouse models of CRC as well as in human samples, and are reversible upon *H. pylori* eradication. These findings provide a basis for assessing *H. pylori* status not only for gastric, but also for colon cancer prevention programmes.

91 RESULTS

92

93 *H. PYLORI* PROMOTES INTESTINAL CARCINOGENESIS IN APC MOUSE 94 MODELS

95 To determine whether *H. pylori* infection promotes the development of tumors in the lower gastrointestinal tract, we infected $Apc^{+/min}$ and $Apc^{+/1638N}$ mice for different time periods (Fig. 96 97 S1A and Fig. S1B). Unexpectedly, *Apc*^{+/min} mice were highly susceptible to the infection, with 98 only 60% of the mice surviving after 12 weeks of *H. pylori* infection (Fig. 1A). An increased tumor burden in the small intestine and colon was observed in infected Apc+min mice 99 compared to uninfected controls (Fig. 1B and 1C). Similar results were observed in $Apc^{+/1638N}$ 100 mice, which not only developed twice as many tumors after infection, but also showed larger 101 tumors in the small intestine (Fig. S1C). Notably, in Apc+/1638N mice, colonic tumors were 102 103 exclusively detected in *H. pylori* infected mice (Fig. S1C). These observations demonstrate 104 that *H. pylori* infection promotes the development of intestinal and colonic tumors in tumor 105 prone mice, while exclusively infecting the stomachs of these mice (Fig S1B).

106

107 *H. PYLORI* INFECTION INDUCES A PRO-INFLAMMATORY RESPONSE IN THE 108 INTESTINE

109 Manipulation of host's T cell immune responses characterizes H. pylori infection and is one 110 the main mechanisms contributing to gastric carcinogenesis. To assess whether alterations 111 in intestinal immunity could be related to the increased tumor burden observed in infected Apc mutant mice, we first analyzed lymphocyte infiltration in the small intestine of Apc^{+/min} and 112 Apc^{+/1638N} mice upon infection. Recruitment of intraepithelial CD3⁺ T cells to small intestine 113 114 and colon was increased upon H. pylori infection (Fig. 2A and Fig. S2A), wich was also 115 confirmed by flow cytometric analysis of T-cells (Fig. S2B and 2C). Furthermore, this 116 revealed a shift towards more CD8⁺ and less CD4⁺ T cells upon infection (Fig. S2D). In addition, the abundance and protein level of Foxp3⁺ regulatory T (Treg) cells was reduced in 117 118 the small intestine from infected mice compared to uninfected controls, as detected by flow 119 cytometry (Fig. 2B and Fig. S2E).

To further explore the underlying mechanisms promoting intestinal tumorigenesis upon *H. pylori* infection independently from tumor-prone backgrounds, we infected wild type C57BL/6 mice (wt) and analyzed immune responses (Fig. S2F). An increased number of intraepithelial CD3⁺ T cells was also observed in the small intestine as well as in the colon of *H. pylori* infected wt mice compared to uninfected controls (Fig. 2C). Contrasting the balanced immune phenotype observed in the stomach (Fig. 2C and Fig. S2G), this was accompanied by a reduction in Foxp3⁺ Treg cells (Fig. 2D and Fig. S2G). Multiplexed

127 ChipCytometry corroborated an overall reduction of Treg cells, and additionally revealed their

128 compartmentalization within the lamina propria in infected colonic tissue (Fig. 2E).

129 We next confirmed the specificity of these T cells for *H. pylori* by restimulating lamina propria

130 CD4⁺T cells with *H. pylori* lysate and measuring the release of the pro-inflammatory cytokine
131 IL-17A, which has been previously described to be one of the main players in the immune

response to *H. pylori* (1). A specific IL-17A/CD4⁺T cell response was observed in infected C57BL/6 and $Apc^{+/min}$ mice (Fig. S2H).

To characterize in depth the specific intestinal immune response elicited by gastric *H. pylori*, we investigated the immune cell compartment on a single cell level by performing 10X singlecell RNA sequencing (scRNAseq). We isolated and sorted single CD45⁺ immune cells of intestinal and colonic tissue from $Apc^{+/min}$ mice and littermate wild type controls that had been infected for 12 weeks with *H. pylori*, and compared them to non-infected controls (Fig. S2I). Unsupervised clustering identified 16 clusters according to their transcriptional profiles, which

are visualized using Uniform Manifold Approximation and Projection (UMAP) (14) (Fig 2F
and Fig. S2J) and were annotated based on known marker genes (Fig. S2K).

To further characterize the Treg cell compartment, we subclustered and annotated Treg cells, which resulted in three subclusters: activated Treg cells (act. Tregs); peripherally derived Treg cells (pTregs), characterized by high RORyt expression; and thymus derived Treg cells (tTregs), characterized by GATA3 expression (15, 16) (Fig. 2G and Fig. S2L). We then computed a Treg effector score (17) (Fig. 2H), and found significantly increased Th17 differentiation genes in infected act. Tregs (Fig. 2H), indicating that *H. pylori* infection reprograms Treg cells into potentially pathogenic Foxp3⁺ IL-17A⁺T cells.

Finally, to understand cell dynamics of T cells in infected mice, we calculated RNA velocity vectors, which predict future states of individual cells based on ratios of spliced and unspliced mRNAs (18). In line with our previous findings, when looking at the CD4 clusters, it was apparent that less CD4 cells were projected towards CD4 Treg cells in infected *Apc* mice (Fig. S2M).

In summary, our results show that *H. pylori* infection induces a *H. pylori* specific proinflammatory immune response in the small intestine and colon of infected mice, that is characterized by loss of regulatory T cells and their differentiation into Foxp3⁺ IL-17A⁺T cells.

157

ACTIVATION OF CARCINOGENIC SIGNALING PATHWAYS AND LOSS OF GOBLET CELLS CHARACTERIZE THE INTESTINAL EPITHELIAL RESPONSE TO *H. PYLORI* INFECTION

161 Considering the alterations induced by *H. pylori* in intestinal immune cells independently of 162 *APC* mutations in wild type mice, we analyzed the effect on signaling pathways putatively 163 mediating the pro-carcinogenic effects of *H. pylori* infection in the epithelium. Therefore, we

assessed transcriptomic profiles of EPCAM⁺ epithelial cells from $Apc^{+/min}$ mice in our scRNAseq data (Fig. S2I). Unsupervised clustering revealed 15 clusters according to their transcriptional profiles, which were visualized as UMAP (Fig. 3A and Fig. S3A) and annotated based on known marker genes (Fig. S3B).

168 Pseudo-spatial distribution of epithelial cells along the crypt-villus axis were computed to 169 confirm correct annotation of cell types (19, 20) (Fig. S3C).

170 Here, we specifically explored signaling pathways associated with CRC initiation and 171 development, namely STAT3 and NF-KB. Notably, these pathways also orchestrate key 172 inflammatory mechanisms in inflammation-driven colon cancer and have been extensively 173 related to *H. pylori* infection (21-23). We computed a score of genes involved in the Jak-STAT signaling pathway, which revealed significantly higher scores in enterocytes and stem 174 cells of wild type and enterocytes of Apc^{+/min} mice upon H. pylori infection (Fig. 3B, Fig. S3D). 175 176 Similarly, when assessing NF-KB signaling in enterocytes, higher scores were observed upon H. pylori infection (Fig. S3E). 177

As it has been shown that activation of epithelial STAT3 favors recruitment of lymphocytes, while inhibiting infiltration of Treg cells in the colon (24), we confirmed hyperactivation of STAT3 in tissue samples from *H. pylori* infected wild type (Fig. 3C) and *Apc* mutant mice (Fig. 3D), which was accompanied by enhanced proliferation as detected by Ki67 staining (Fig. 3C).

Given that a functional intestinal barrier is depending on mucus replenishment by goblet cells, we next assessed their status by Periodic acid Schiff (PAS) staining. We observed reduced number of mucus producing cells in the small intestine and in the colon of *H. pylori* infected wild type (Fig. 3C) and *Apc* mutant mice (Fig. 3E) compared to uninfected controls.

187 To explore in depth the effects of *H. pylori* infection on the goblet cells, we clustered and 188 annotated goblet cells in our scRNAseq data set based on goblet cell differentiation markers 189 (25). This revealed immature, characterized by high expression of Tff3; intermediate, highly 190 expressing Oasis; and terminal goblet cells, with high expression of Muc2 and Klf4 (Fig. S3F 191 and Fig. S3G). Maturational states were distinctly affected by *H. pylori* infection, with a switch 192 to less differentiated goblet cells (Fig. S3H). To assess goblet cell functionality, we assessed the expression of antimicrobial peptide genes Reg3b and Reg3g, which are known to play a 193 194 role in response to pathogens and inflammation (26). We found them to be reduced upon H. 195 pylori infection (Fig. S3I). These findings are consistent with a compromised intestinal barrier integrity induced by *H. pylori* infection, independent of *APC* status. 196

To explain the absolute loss of goblet cells we observed in infected mice, we studied cellular dynamics of goblet cells by means of RNA velocities. In the colon, we observed less directionality from the stem cell cluster towards the goblet cell cluster, and at the same time a higher projection towards the colonocyte cluster upon *H. pylori* infection (Fig. S3J), in

contrast to the small intestinal goblet cell cluster, where cell dynamics seem to be restricted to the goblet cell cluster itself. When assessing the expression of Atoh1, which is known to drive terminal differentiation into the secretory lineage (27), in stem cells of both small intestine and colon, a significiantly lower expression was found upon *H. pylori* infection (Fig. S3K). These findings indicate a skewed differentiation of stem cells rather into unspecialized colonozytes than into goblet cells.

Together, these results indicate that *H. pylori* induces carcinogenic signaling pathways and has a detrimental impact on mucus producing goblet cells in the small intestine and colon of wt and *Apc* mutant mice.

210

H. PYLORI INFECTION FAVORS THE PRESENCE OF MUCUS-DEGRADING MICROBIOTA

213 Microbiota alterations and aberrant presence of certain bacterial species in the small 214 intestine have been related to the development of CRC (28). This could be an additional 215 mechanism by which H. pylori contributes to intestinal carcinogenesis, since H. pylori 216 infection has been shown to alter microbiota signatures (29). Therefore, we assessed to 217 which extent H. pylori infection influenced small intestinal and colonic microbial composition 218 by performing 16S RNA sequencing. While we found significantly increased abundance of 219 Helicobacter spp. in the stomach, we did not detect H. pylori in intestine and colon (Fig. 220 S4A). When comparing the microbiota in caecum and colon of infected and non-infected 221 mice via taxonomic profiling, we observed apparent changes at phylum level upon H. pylori 222 infection (Fig. 4A). Furthermore, we found signs of decreased α -diversity in small intestine 223 upon *H. pylori* infection (Fig. S4B) as well as significantly different β -diversity in caecum, 224 stool and small intestine between non-infected and infected mice (Fig. S4C). Differential 225 abundance testing revealed Akkermansia spp. to be enriched in infected wt mice (Fig. S4D, 226 Fig. 4B). When exploring the data for further species sharing the mucus-degrading 227 characteristics of Akkermansia spp., we found an increase in Ruminococcus spp. (Fig. 4B 228 and Fig. S4D). The abundance of both species was also higher in Apc mutant mice upon H. 229 pylori infection (Fig. 4C and 4D).

Together, *H. pylori* alters the microbiota of the lower gastrointestinal tract and induces
 distinct mucus-degrading signatures in both wt and *Apc* mutant mice.

232

H. PYLORI INDUCED COLORECTAL CARCINOGENESIS IS PREVENTED BY ERADICATION

The interplay between a pro-inflammatory response and activation of pro-carcinogenic signaling, accompanied by alterations in microbiota characterized *H. pylori*-driven intestinal tumorigenesis. To dissect the contribution of inflammation in the absence of microbiota, we

infected $Apc^{+/1638N}$ mice under germ-free conditions (Fig. S5A and 5B). We observed similar 238 239 immune alterations as in specific-pathogen free (SPF) mice, namely increased CD3⁺ T cell 240 infiltration and reduction of Treg cells in small intestine and colon (Fig. 5A, Fig. S5D and 5B). 241 In contrast, germ-free mice barely showed activation of STAT3 signaling, and no reduction of 242 goblet cells upon H. pylori infection (Fig. 5C and 5D, Fig. S5D). Finally, we still observed a 243 higher tumor number in *H. pylori* infected germ-free mice, albeit not significant (Fig. 5E). In 244 order to ultimately assess the contribution of H. pylori induced changes in microbiota to 245 intestinal carcinogenesis, we performed a stool transfer experiment. Stool was obtained from 4 different groups, namely SPF non-infected and *H. pylori* infected Apc^{+/1638N} and Apc^{+/+} mice, 246 respectively, and transferred into germ-free Apc+/1638N mice (Fig. S5C). Higher tumor 247 numbers in stool recipients from H. pylori infected mice were found, which was already 248 evident in Apc^{+/+} mice and further enhanced in an Apc^{+/1638N} background (Fig. 5F). This 249 250 indicates a strong contribution of H. pylori-induced changes in microbiota to the tumor 251 phenotype and suggests, that H. pylori-induced carcinogenesis in the small intestine and 252 colon is a multifactorial process involving the interplay of the pro-inflammatory immune 253 response, alterations in microbiota and procarcinogenic signaling. Therefore, we next sought to determine whether eradication of *H. pylori* infection could abrogate the carcinogenic 254 255 process, by treating the mice with a triple therapy regimen consisting of clarithromycin, 256 metronidazole and omeprazole (30), reflecting the "Italian triple therapy" regimen also used 257 in infected patients to eradicate *H. pylori* (Fig. 5G and Fig. S5E). Importantly, we found that 258 after antibiotic eradication, tumor burden was at the same levels as in uninfected controls 259 (Fig. 5H). To delineate that the underlying changes in the intestinal immune response were 260 directly induced by H. pylori infection and independent of mutated Apc, we analyzed the 261 effect of H. pylori eradication on C57Bl/6 mice (Fig. 5G), and found a lower CD3⁺ T cell 262 infiltration in the stomach (Fig. S5F), small intestine and colon (Fig. 5I, Fig. S5G) compared 263 to infected mice at 4 and 12 weeks post eradication. The percentage of Treg cells was 264 initially reduced in eradicated mice 4 weeks after treatment, while 12 weeks post-treatment, 265 the percentage of FoxP3⁺ T cells was observed to recover (Fig. 5J). A specific IL-17A/CD4⁺T cell response was observed in infected mice, which was initially lost after eradication therapy, 266 but then reappeared after longer recovery time (Fig. 5K), supporting the specificity of the 267 268 response to H. pylori, based on the given antigen encounter and response also in eradicated 269 mice. Importantly, the clearance of infection resulted in normalization of STAT3 activation 270 and the number of PAS positive cells (Fig. 5L and Fig. S5G), confirming that H. pylori is 271 specifically responsible for these changes.

In summary, our results demonstrate that *H. pylori* directly enhances colon carcinogenesis by shaping intestinal and colonic immune responses and inducing profound changes in intestinal/colonic microbiota and epithelial homeostasis. Eradication of *H. pylori* infection

prevents its tumor-promoting effects also in the colon, providing a possible additionalstrategy to reduce CRC burden.

277

278 H. PYLORI ALTERS COLONIC HOMEOSTASIS IN HUMAN

279 Our mouse models showed that H. pylori affects intestinal and colonic homeostasis at 280 different cellular and molecular levels, which can ultimately enhance tumor development. To 281 determine whether these effects were also observed in humans, we analyzed immune 282 signatures in a cohort of 154 human colon tissue samples. Based on immune responses and 283 histology of the stomach, we stratified samples according to *H. pylori* status into currently 284 (actively) infected and eradicated patients. We found that H. pylori-actively infected as well 285 as eradicated individuals showed higher infiltration of CD3⁺ T cells in the colon compared to 286 uninfected subjects (Fig. 6A). Using endoscopy-derived colon biopsies, we further 287 characterized T cell responses by flow cytometry, which revealed tendencies towards more 288 CD3⁺ T cells in the colonic mucosa of currently infected patients (Fig. S6A). In contrast, CD4⁺ 289 and CD8⁺ subsets were not affected by *H. pylori* status (Fig. S6B). Notably, the number of 290 FoxP3⁺ cells in the colonic mucosa was lowest in the currently infected group, whereas 291 eradicated patients seem to level with negative controls (Fig. 6C). The overall loss of Tregs 292 was confirmed via ChipCytometry (Fig. 6B), which additionally showed that intraepithelial 293 localization of Tregs is almost lost in colon samples from *H. pylori* infected individuals (Fig. 294 6B and Fig. S6C).

We next focused on the epithelial compartment and, in concordance with our findings in mice and our eradication experiments, found a higher number of p-STAT3 positive epithelial cells and a concomitant loss of mucus producing cells in the colon of currently infected subjects, which was attenuated in eradicated patients (Fig. 6A).

Finally, we assessed microbial changes in stool of patients and found a difference in β diversity between actively *H. pylori* infected and negative patients (p=0.062), but not between *H. pylori* eradicated and negative patients (p=0.552) (Fig. 6D). In contrast, we neither detected significant changes in alpha-diversity (Fig. S6D) nor in Firmicutes to Bacteroidetes ratio (Fig. S6E) between the 3 groups. Comparative microbiome profiling revealed *Prevotellaceae* and *Peptostreptococcales*, which have been associated with CRC, to be differentially abundant in *H. pylori* positive patients (Fig. S6F and Fig. S6G).

These results confirm that the immune and epithelial signatures identified in mouse models upon *H. pylori* infection are also observed in humans, and are accompanied by changes in microbiota compositions, which can further contribute to colon carcinogenesis. Furthermore, the attenuated phenotype observed in *H. pylori* eradicated patients further supports *H. pylori* status as an independent risk factor for CRC and simultaneously offers an option for CRC prevention for those patients at risk.

312

313 **DISCUSSION**

314 Although selectively colonizing the stomach, chronic H. pylori infection is associated with 315 several extragastric diseases (31). Epidemiological data indicates an association between H. 316 pylori infection and a higher risk and aggressiveness of colorectal cancer (CRC), with an 317 odds ratio (OR) of 1.9 (32), an OR higher than for most other known risk factors, such as 318 smoking, alcohol and BMI (32). However, these epidemiological data have not yet been 319 confirmed experimentally, and a molecular mechanism by which H. pylori may promote CRC remained elusive. We employed Apc mutant mouse lines (Apc^{+/min} and Apc^{+/1638N}) as surrogate 320 321 models for human CRC, and observed a nearly two-fold increase in tumor numbers in mice 322 infected with *H. pylori*, which coincides with the OR observed in epidemiological studies. 323 Remarkably, this increase was not only observed in the small intestine, where both models 324 usually show most tumors, but was especially evident in the colon. This prompted us to 325 decipher the potential mechanisms driving H. pylori-induced carcinogenesis in the small 326 intestine and colon.

327 The effects of *H. pylori* infection on other organs are best understood for the lung, where 328 chronic *H. pylori* infection imposes a regulatory immune signature that protects from asthma 329 disease (33). In contrast to these observations, we observed an H. pylori antigen-specific 330 pro-inflammatory Th17 mediated response in the small intestine and colon, which was not 331 balanced by an increase in Treg cells, as it occurs in the stomach or lung. The immune 332 response mounted towards *H. pylori* originates from Peyer's patches in the gut (2), which 333 may explain why *H. pylori* specific T cells also homed to intestinal and colonic mucosal sites. 334 Interestingly, IL-17 was not only found to be increased in H. pylori positive patients with 335 gastritis and gastric cancer (34), but also in CRC, where Th17 signatures, including RORC, 336 IL17, IL23 and STAT3, were linked to poorer prognosis (35). Still, it was surprising to observe 337 a loss of intestinal Treg cells, which also contrasts the balanced immune response usually 338 observed in the stomach upon H. pylori infection. Additionally, we found that in the lower GI 339 tract, Tregs were reprogrammed to upregulate Th17 differentiation markers. Murine and 340 human studies have demonstrated that Treg cells can be reprogrammed to a distinct 341 population, Foxp3⁺/IL17⁺T cells, phenotypically and functionally resembling Th17 cells (36). 342 Particularly in CRC, the presence of Foxp3⁺/IL17⁺T cells has been reported to be increased 343 in the mucosa and peripheral blood of chronic colitis patients as well as in colorectal tumors 344 (37). Foxp $3^+/IL17^+$ cells were shown to promote the development of tumor-initiating cells by 345 increasing the expression of several CRC-associated markers such as CD44 and epithelial 346 cell adhesion molecule EPCAM in bone marrow-derived mononuclear cells (38). Thus, the 347 pro-inflammatory Th17 response elicited by H. pylori, especially the differentiation of Treg 348 cells to a Th17 phenotype, may constitute one of the major mechanisms enhancing tumor

development. This is in line with literature showing that altered T cell homeostasis is a key
event during colorectal carcinogenesis, not only driving tumor development and progression,
but also determining treatment response of CRC patients (39).

352 Mutations in the gene encoding adenomatous polyposis coli (APC) are the most frequent 353 driver mutations leading to sporadic CRC, together with mutations in TP53 and KRAS (40, 354 41). Pro-inflammatory and proliferative signaling pathways such as STAT3, NF-κB and WNT 355 signaling, activated by signals derived from epithelial and immune cells, drive chronic 356 inflammation, a known mechanism contributing to CRC (23, 42). CRC risk is markedly 357 increased in patients with chronic inflammatory bowel disease (IBD), with the risk rising with 358 the duration of disease, from 8.3% after 20 years, to 18.4% after 30 years (43). 359 Mechanistically, besides immune signaling by Th17 cells, activation of pro-inflammatory 360 signaling pathways as well as altered microbiota, contribute to the pathogenesis of colitis-361 associated cancer (44).

362 The strong pro-inflammatory response induced locally by *H. pylori* in the small intestine was 363 accompanied by the activation of NF-kB and STAT3 pathways. Activation of STAT3 signaling 364 has been strongly related to tumor initiation, development and progression, while levels of 365 activated STAT3 in the tissue correlate with tumor invasion, TNM stage and reduced overall survival of CRC patients (45). In addition, the activation of epithelial STAT3 was reported to 366 367 downregulate the expression of chemokines important for the recruitment of Treg cells in the 368 intestine (24). Therfore, it is tempting to speculate that during *H. pylori* infection, activation of 369 STAT3 in intestinal and colonic epithelial cells contributes to loss of Treg recruitment, thereby 370 supporting malignant transformation of the intestinal tissue. This central role for STAT3 371 during carcinogenesis in the intestine is supported by the fact that depletion of STAT3 in Apc^{+/min} mice led to a reduction in the incidence of early adenomas (46). Importantly, we 372 373 observed a reduction and normalization of STAT3 levels after eradication of *H. pylori*, which 374 resulted in a normalization of tumor load. Notably, for eradication, a treatment regimen also 375 applied in humans was used in order to be able to translate the results to humans.

376 The function of STAT3 as oncogene or tumor suppressor seems to be determined by the 377 milieu eliciting its activation as well as the local gut microbiota (47), which is increasingly 378 recognized as an important regulator of colonic cancer development (48). Interestingly, 379 microbial induction of IL-17A production has been shown to endorse colon cancer initiation and progression in Apc^{+min} mice, which was mediated via STAT3 signaling (49). We thus 380 381 hypothesized that alterations in microbiota compositions in the intestine and colon induced 382 by H. pylori may also contribute to carcinogenesis (29, 50). Indeed, when housing mice 383 under germ-free conditions, activation of STAT3 and tumor development were lower upon H.

pylori infection, but not completely normalized, indicating that microbiota alterations are
 involved in the phenotype but not exclusively responsible.

386 Such disturbances in gut microbiota communities have been shown to contribute to CRC 387 development and progression (28). H. pylori is known to affect not only local gastric 388 microbiota, but also distant microbial populations in intestine and colon (29, 51). It has been 389 shown that inflammation-driven dysregulation of microbiota can promote colorectal tumor 390 formation and progression (52) and that in response to bacterial stimuli or pathogen 391 associated molecular receptors, pro-inflammatory pathways such as c-Jun/JNK and STAT3 signaling pathways are activated and accelerate intestinal tumor growth in Apc^{+/min} mice (47). 392 393 This was supported by our findings from transferring stool of *H. pylori*-infected SPF mice into +/1638N germ-free Apc mice, where we observed an accelerated tumor development in 394 395 comparison to stool transferred from non-infected mice. Together, these data indicate that H. 396 pylori induced microbial signatures are involved in and indispensable to promote intestinal 397 tumor growth.

398 Our data revealed a distinct mucus-degrading microbiota signature associated with H. pylori 399 infection in mice, namely enrichment with Akkermansia spp. and Ruminococcus spp., while 400 in human samples from H. pylori infected patients, bacterial taxa associated with CRC, 401 Prevotellaceae and Peptostreptococcales, were found (28). Although some studies 402 established an inverse correlation between the presence of Akkermansia and gastrointestinal 403 diseases (53), Akkermansia has been reported to be increased in CRC patients most likely 404 due to the overexpression of certain mucins in the tumors (54). Notably, we also observed a 405 general loss of goblet cells, which are important to produce mucins and antimicrobial 406 peptides. This loss of goblet cells was also observed in clinical samples from H. pylori 407 infected patients undergoing colonoscopy. Thus, *H. pylori* infection disrupts, by two distinct 408 mechanisms, intestinal mucus integrity essential to maintain a healthy barrier to impair 409 bacterial penetration. In the absence of a sufficient regulatory T cell response – as observed 410 here -, which normally keeps inflammatory signals at bay, the carefully balanced 411 homeostasis maintained in the gut by the interplay of a "healthy" microbiome and an intact 412 mucosa then fails to balance the proinflammatory signature elicited by H. pylori infection, 413 enabling carcinogenesis. Eradication of H. pylori restored intestinal homeostasis with 414 reappearance of goblet cells and normalized the intestinal immune signature, which then 415 completely abrogated the tumor-promoting effect.

Importantly, when analyzing colonic biopsies from *H. pylori* infected patients, we could observe the very same alterations as seen in mice, with activation of pro-carcinogenic signaling pathways and a significant reduction in Treg cells, and an increase of CD3⁺ cells. The attenuated phenotype in eradicated patients highlight the clinical relevance of our

findings and indicate, that *H. pylori* infection is more than a mere risk factor for colon carcinogenesis, but actively promotes a procarcinogenic niche in the colon, that may be prevented by eradication of *H. pylori*, which therefore could decrease the risk of CRC development in infected individuals. However, studies showing a correlation between *H. pylori* infection and CRC did not address the effect of antibiotic therapy. The inclusion of such cohorts in future studies is important to determine the impact of *H. pylori* eradication in CRC development.

In summary, our study not only provides solid experimental evidence that *H. pylori* infection
accelerates tumor development, but also offers insight into the underlying mechanisms and
suggests *H. pylori* screening and eradication as a potential measure for CRC prevention
strategies.

- 431
- 432

433 ACKNOWLEDGEMENTS

434 We thank members of the laboratory 'Chronic inflammation and carcinogenesis' for experimental help as well as critical discussion, with special thanks to Maximilian Koch, Karin 435 436 Taxauer, Martin Skerhut and Teresa Burrell for experimental support. We thank Julia 437 Horstmann and the team of the ColoBac study at the Klinik und Poliklinik für Innere Medizin 438 II, Klinikum rechts der Isar, for the supply of human biopsies. We thank Core Facility 439 Mikrobiom of the ZIEL Institute for Food & Health, Technical University of Munich, for 16S 440 rRNA Sequencing services, as well as Dharmesh Singh and Nyssa Cullin. We thank Core 441 Facility Gnotobiology of the ZIEL Institute for Food & Health, Technical University of Munich, for germ-free mice. 442

443 **FUNDING**

This work was funded by the Deutsche Forschungsgemeinschaft (DFG [German Research
Foundation]) SFB1371/1-395357507 (project P09).

446 AUTHOR CONTRIBUTIONS

447 A.R., R.M.L and M.G. conceived the study. A.R., A.D. and R.M.L. designed and analyzed 448 experiments. S.J. contributed and provided code and support to single cell RNA sequencing 449 and chip cytometry. V.E. and A.W. contributed to experiments. A.D., S.J, and R.M.L 450 contributed to data interpretation. M.V. and M.Q. provided human biopsies. K.P.J. provided 451 mouse models and critically revised the article. D.H., D.H.B. and L.D. critically revised the 452 article. A.R. and R.M.L. wrote the article. A.R., R.M.L. and M.G. revised the article. M.G. 453 acquired the funding. All authors read and reviewed the article.

454 COMPETING INTERESTS

455 The authors declare no competing interests.

456 DATA AVAILABILITY

- 457 Raw single cell RNA sequencing and 16S rRNA sequencing data are available under the
- 458 BioProject ID PRJNA808836.
- 459

460 MATERIALS AND METHODS

461

462 STUDY DESIGN

This study was conceptualized to investigate the underlying mechanisms of *H. pylori* induced colorectal carcinogenesis.

Tumor mouse models $Apc^{+/min}$, initially obtained from Jackson Laboratories, and $Apc^{+/1638N}$ mice, provided by Prof. Klaus-Peter Janssen (Klinikum rechts der Isar, München) (41), were bred under specific pathogen-free conditions at our animal facility at the Technical University of Munich. Both female and male mice were used and co-housed with littermate controls.

469 Apc^{+/1638N} mice and wild type littermates were re-derived germ-free from conventional mice

470 by Prof. Bleich and Dr. Basic (Hannover medical school, Hannover).

Female C57BL/6 mice were purchased from Envigo RMS GmbH at an age of 6 weeks and acclimatized to our animal facility for 1-2 weeks prior infection. Mice were fed with a standard diet and water ad libitum and maintained under a 12-hour light-dark cycle. DNA extracted from mouse tails was used for genotyping. All animal experiments were conducted in compliance with European guidelines for the care and use of laboratory animals and were approved by the Bavarian Government (Regierung von Oberbayern, Az.55.2-1-54-2532-161-2017).

87 fresh colonoscopy biopsies were collected within the framework of the COLOBAC study
of the CRC1371 (Dept. of Surgery and II. Medical Dept. Klinikum rechts der Isar, Technical
University of Munich, Germany). 67 FFPE colon biopsies were obtained from the Klinikum
Bayreuth. Both studies were approved by the respective ethics committees (Klinikum rechts
der Isar #322/18, Klinikum Bayreuth #241_20Bc).

H. pylori status of colonoscopy biopsies was determined in serum samples using the
 recomwell Helicobacter IgG kit (Mikrogen) according to manufacturer's instructions. *H. pylori* status of FFPE biopsies was determined histologically in corresponding gastric biopsies by
 Prof. Michael Vieth.

487

488 RANDOMISATION AND BLINDING

Animals were randomly distributed to control/infection groups. The infection status of mice was known to the investigating researcher. *H. pylori* status of patients was not known to the researcher during sample analysis.

492

493 *H. PYLORI* INFECTION

H. pylori pre-mouse Sidney Strain 1 (PMSS1) was cultured on Wilkins-Chalgren (WC) Dent
(containing vancomycin, trimethoprim, cefsoludin and amphotericin) agar plates in a
microaerophilic atmosphere (5% O2, 10% CO2). 6–8-week old mice were orally gavaged

twice within 72 hours with 2×10^8 *H. pylori* PMSS1 in 200 µl brain-heart-infusion (BHI) medium containing 20% fetal calve serum (FCS). Infection status was determined by plating homogenized stomach tissue on WC Dent plates supplemented with 200 g/ml bacitracin, 10 g/ml nalidixic acid and 3 g/ml polymycin B, and counting colony-forming units (CFU).

501

502 H. PYLORI ERADICATION

After 4 weeks of infection, *H. pylori* eradication was performed with an antibiotic cocktail containing clarithromycin (Eberth) (7.15 mg/kg/day), metronidazole (Carl Roth) (14.2 mg/kg/day) and the proton-pump inhibitor omeprazole (Carl Roth) (400 µmol/kg/day) by oral gavage twice daily for 7 consecutive days. Omeprazole was dissolved in 200µl 2.5% Hydroxy-propyl-methyl-cellulose (Sigma-Aldrich) with pH adjusted to 9. Antibiotics, dissolved in 200µl PBS, were administered 45 minutes after omeprazole (30).

509

510 STOOL TRANSFER

511 SPF $Apc^{+/1638N}$ mice and wild type littermates were infected at an age of 6-8 weeks and after 512 24 weeks of infection, stool pellets were collected from these "donor" mice, dissolved in 513 0.1ml PBS/g stool and administered via oral gavage to germ-free $Apc^{+/1638N}$ "recipient" mice.

514

515 HISTOLOGY AND IMMUNOHISTOCHEMISTRY

516 Small intestine and colon were longitudinally opened and flushed with phosphate-buffered 517 saline (PBS). Solid neoplastic lesions were assessed and measured macroscopically by two 518 independent examiners. Dissected tissue was fixed in 4% formaldehyde, embedded in 519 paraffin and 4µm thick sections were used for staining. For immunohistochemical stainings, 520 antigen retrieval was achieved with 10 mM sodium citrate (pH 6) or 1 mM EDTA (pH 8), and primary antibodies were applied overnight at 4°C (Table 1). Horseradish peroxidase (HRP) 521 522 coupled secondary antibodies (Promega) and diaminobenzidine (DAB) (CellSignaling) were 523 used to detect signal. Periodic acid Schiff (PAS) (Carl Roth) staining was performed to 524 assess the quantity of mucus producing goblet cells. Stomach, intestinal and colonic sections 525 were blindly quantified by two independent researchers by measuring the area of a functional 526 unit (stomach gland, intestinal crypt/villus unit or colonic crypt) and counting positive cells per 527 mm², using Aperio ImageScope (Leica BioSystems).

528

529 **Table 1. Antibodies used for immunohistochemical evaluation.**

Target	Clone	Origin/Target	Antigen retrieval	Dilution	Company
CD3	SP7	Rabbit mAB	sodium citrate	1:150	Thermo Fisher
Ki67	D3B5	Rabbit mAB	sodium citrate	1:400	Cell Signaling
pSTAT3	D3A7	Rabbit mAB	EDTA	1:200	Cell Signaling

531

532 CHIPCYTOMETRY AND AUTOMATIC IMAGE QUANTIFICATION

533 Murine intestinal and colonic cross-sections were preserved with O.C.T. compound (Tissue 534 Tek) in cryomolds (Tissue Tek) and kept frozen at -80°C. For ChipCytometry, 7µm thick 535 sections were cut on a Cryostat (Leica), fixed in Fixation Buffer (ZELLKRAFTWERK) for 45 536 subsequently transferred to CellSafe Chips (ZELLKRAFTWERK). minutes and 537 ChipCytometry on human FFPE biopsies was performed according to the procedure 538 described in Jarosch, Köhlen et al (55). Briefly, tissue sections were rehydrated on coverslips 539 and antigen retrieval was performed using TRIS-EDTA buffer (pH 8.5) and then transferred 540 to CellSafe Chips (ZELLKRAFTWERK). Alternating cycles of staining, immunofluorescence 541 detection and photobleaching were performed for various markers (Table 2). Automated image processing was performed as described in Jarosch, Köhlen et al., which includes 542 543 segmentation of cells, removing of outliers and spatial spill over correction (55). The resulting cell - marker matrix was analyzed using FlowJo software (V10.8.0), which enabled absolute 544 545 quantification of cells.

546

547 Table 2. Antibodies used for ChipCytometry.

Epitope	Fluorochrome	Clone	Dilution	Company	Catalog #
anti-mouse CD3	PerCP/Cy5.5	17A2	1:200	BioLegend	100218
anti-mouse CD4	eFluor450	RM4-5	1:80	BioLegend	100531
anti-mouse CD45	FITC	30-F11	1:100	BioLegend	103108
anti-mouse Foxp3	PE	FJK-16s	1:80	eBioscience	14-5773-82
Pan-cytokeratin	AlexaFluor 488	C-11	1:100	BioLegend	628602
Hoechst	BUV395	-	1:50.000	ThermoScientific	H3570
α-SMA	eFluor570	1A4	1:750	eBioscience	41-9760-80
anti-human CD3	unconjugated	SP7	1:150	ThermoScientific	RM-9107-S1
anti-human CD4	AlexaFluor 488	polyclonal	1:50	R&D Systems	FAB8165G
anti-human CD45	PerCP/Cy5.5	HI30	1:80	BioLegend	304028
anti-human Foxp3	PE	236A/E7	1:30	eBioscience	563791
2 nd anti-rabbit	PE	Polyclonal	1:300	BioLegend	406421

548

549 LAMINA PROPRIA AND INTRAEPITHELIAL LYMPHOCYTE ISOLATION AND

550 FLOW CYTOMETRY

Harvested intestinal tissue was cut open longitudinally after removing Peyer's Patches and
adjacent tissue. Subsequently, tissue was treated with 30mM EDTA, filtered supernatants
were collected as intraepithelial lymphocytes and remaining tissue was digested with
0.5mg/mL collagenase from Clostridium histolyticum Type IV (Sigma Aldrich) and 10µg/mL
DNase I (Applichem). Filtered and centrifuged lamina propria cell suspensions were density
separated using a Percoll gradient (Thermo Fisher).

557 Fresh human biopsies were collected in Hank's Balanced Salt Solution w/o Mg²⁺/Ca²⁺ 558 (HBSS) and digested with 0.1% collagenase from Clostridium histolyticum Type IV (Sigma 559 Aldrich) for 30 min. at 37°C. Digestion was stopped by adding 20 mL HBSS and 560 centrifugation twice. Isolated lymphocytes were frozen in Dimethyl sulfoxide (Applichem) + 561 20 % FCS at -80° C.

562 Single cell suspensions were blocked with anti-mouse CD16/CD32 or anti human TruStain 563 FcX and live/dead staining performed with Zombie Aqua (BioLegend) in PBS. Surface 564 antibodies (Table 3) were diluted according to titration experiments and cells stained for 30 min at 4° C. For transcription factors, Foxp3 Transcription Factor Staining Buffer Set 565 566 (eBioscience) was used according to manufacturer's instructions. For stimulation with whole H. pylori lysate, cells were stimulated for 12 hours with 20µg/mL PMSS1 lysate at 37° C and 567 protein transport inhibitor Golgi Plug (BD Biosciences) added 1:1000 after 7 hours for a total 568 569 of 5 hours. Stimulated cells were stained with intracellular cytokine staining kit according manufacturer's instructions (BD Biosciences). Stained single cell suspensions were acquired 570 on a CytoFlex S (Beckman Coulter) and analyzed using FlowJo software (V10.8.0). 571

572

573	Table 3. Antibodies used	d for flow cytometry.

Epitope	Fluorochrome	Clone	Dilution	Catalog #	Company
anti-mouse CD16/CD32	-	93	1:500	14-0161-86	eBioscience
anti-mouse CD45	AlexaFluor 700	30-F11	1:400	103128	BioLegend
anti-mouse CD3ɛ	FITC	500A2	1:200	152304	BioLegend
anit-mouse CD4	BV605	RM4-5	1:250	100548	BioLegend
anti-mouse CD4	eFluor450	RM4-5	1:250	48-0042-82	eBioscience
anti-mouse CD8a	APC-H7	53.6-7	1:250	560182	BD Biosciences
anti-mouse FoxP3	eFluor450	FJKL-16s	1:200	45-5773-82	eBioscience
anti-mouse IL-17A	APC	eBio17B7	1:150	17-7177-81	eBioscience
anti-human CD45	AlexaFluor 700	2D1	1:50	368514	BioLegend
anti-human CD3	FITC	OKT3	1:300	317306	BioLegend
anti-human CD4	PB450	SK3	1:30	344620	BioLegend
anti-human CD8	APC-H7	SK1 (RUO)	1:150	560179	BD Biosciences
anti-human FoxP3	PerCP/Cy5.5	PCH101		35-4776-42	eBioscience
Human TruStain FcX	-	-	1:500	422302	BioLegend

574

575 SINGLE CELL RNA SEQUENCING

Intestinal and colonic tissue was harvested and cells were isolated as described in section
"Lymphocyte isolation and Flow cytometry". Single cell suspensions were stained with antimouse CD45 PB450 (Clone: 30-F11, BioLegend, #103126), anti-mouse EPCAM APC
(Clone: G8.8, BioLegend, #118214) and Propidium Iodide (PI). CD45+ PI- and EPCAM+ PIcells were sorted.

581 For cell hashing TotalSeq-B anti-mouse Hashtags 1, 2 and 5 to 8 (M1/42; 30-F11, Biolegend,

582 155831, 155833, 155839, 155841, 155843, 155845) were used at a dilution of 1:50.

Single cell RNA Sequencing was performed with 10X Genomics, according to manufacturer's instructions (Chromium[™] Single Cell 3' GEM v3 kit). Sorted cells were centrifuged and resuspended in mastermix and 37.8 µl of water, before 70 µl of the cell suspension was transferred to the chip. QC was performed with a high sensitivity DNA Kit (Agilent) on a Bioanalyzer 2100, and libraries were quantified with the Qubit dsDNA HS assay kit (life technologies).

Libraries were pooled according to their minimal required read counts (20.000 reads/cell for

gene expression libraries). Illumina paired end sequencing was performed with 150 cycles ona NovaSeq 6000.

592 Annotation was performed using cellranger (V5.0.0, 10X genomics) against 593 the murine reference genome GRCm38 (mm10-2020-A). All subsequent analysis was 594 performed using SCANPY V1.6 (56). Preprocessing was performed following the guidelines 595 of best practice in single-cell RNA-seq analysis (57) and involved less than 15% 596 mitochondrial genes, regressing out cell cycle, mitochondrial genes and total counts. The 597 data was normalized per cell count and logarithmized. Genes used for gene scores are listed 598 in Table S1 and the scores were computed with the SCANPY build in function 599 "sc.tl.score genes".

600 RNA velocities were calculated using velocyto (18) and analyzed with scVelo (V 0.2.3) (58).

601

602 **16S RRNA SEQUENCING**

603 Bacterial DNA extraction and 16S rRNA sequencing was either performed as described 604 previously (59, 60) by the Core Facility Microbiome of the ZIEL Institute for Food & Health 605 (Technical University of Munich) or as follows: small intestine and colon tissue were 606 homogenized with a Precellys® 24 homogeniser (Avantor). Phenol chloroform DNA isolation 607 and ethanol precipitation were performed following modified protocols of P.J. Turnbaugh et 608 al., 2009 and E. G. Zoetendal et al. 2006 (61, 62). Subsequently, the V3/V4 region of 609 the 16S rRNA gene was amplified and double indexed using barcoding primers modeled 610 after Kozich et al. PCR fragments were purified using magnetic AMPure XP beads (Beckman 611 Coulter, USA) according to manufacturer's instructions (63). The final pooled library 612 was sequenced on an Illumina MiSeq with Reagent Kit v3 (Ilumina) for 600 cycles of paired-613 end reads.

Raw sequences were analyzed using the Qiime2 platform (v2021.4) (64). In detail, denoising, removing of chimeras and generation of Amplicon Sequence Variants (ASVs) was performed with dada2. Subsequently, a phylogenetic tree was generated and diversity measures were calculated. Chao1 index was used to determine community alpha diversity.

Taxonomic classification was performed with a qiime2 feature classifier trained on the SILVA132 99% OTUs, specifically targeting the V3 region. Linear discriminant analysis effect size (LEfSe) determining differentially abundant features was performed on the online interface at http://huttenhower.sph.harvard.edu/lefse/, developed by Segata et al. (65).

622

623 **QUANTITATIVE PCR**

624 Stomach, small intestine and colon tissue were homogenized with Precellys® 24 625 homogeniser (Avantor) and RNA isolation was performed with a Maxwell 48 RSC simply 626 RNA Tissue Kit on a Maxwell RSC Instrument (Promega). cDNA was synthesized with 627 Moloney Murine Leukemia Virus Reverse Transcriptase RNase H- Point Mutant (Promega). 628 Gene expression was assessed with GoTaq qPCR Mastermix (Promega) on a CFX384 629 system (Bio-Rad). The quantitative PCR consisted of 40 cycles of amplification with 15 sec 630 denaturation at 95 °C. 1 min annealing and amplification at 60 °C. According to the $\Delta\Delta$ CT 631 method, CT values were normalized to Gapdh and to uninfected controls, in order to 632 determine fold changes in gene expression. The sequences of primers used are summarized 633 in Table 3.

634

635 Table 3. Primer sequences used for qPCR.

Gene	Forward sequence	Reverse sequence
Gapdh	GCCTTCTCCATGGTGGTGAA	GCACAGTCAAGGCCGAGAAT
<i>Foxp</i> 3	AGGAGCCGCAAGCTAAAAGC	TGCCTTCGTGCCCACTGT

636

637 STATISTICAL ANALYSIS

Statistical analysis was conducted on biological replicates as stated in the Fig. legends. Depending on Gaussian distribution, statistical significance between two groups was determined with unpaired student's t-test or Mann-Whitney-U test and for analysis among more than two groups, one-way ANOVA with Tukey's multiple-comparisons test or Kruskal-Wallis-test with Dunn's multiple-comparisons test. P values below 0.05 were considered significant. Exact p values are stated when relevant. Statistical analysis was carried out using Prism 8 (GraphPad Software).

645

646

647

648 **REFERENCES**

Shi Y, Liu XF, Zhuang Y, Zhang JY, Liu T, Yin Z, et al. Helicobacter pylori-induced
Th17 responses modulate Th1 cell responses, benefit bacterial growth, and contribute to
pathology in mice. J Immunol. 2010;184(9):5121-9.

Angai S, Mimuro H, Yamada T, Baba Y, Moro K, Nochi T, et al. Role of Peyer's
patches in the induction of Helicobacter pylori-induced gastritis. Proc Natl Acad Sci U S A.
2007;104(21):8971-6.

3. Censini S, Lange C, Xiang Z, Crabtree JE, Ghiara P, Borodovsky M, et al. cag, a
pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated
virulence factors. Proceedings of the National Academy of Sciences of the United States of
America. 1996;93(25):14648-53.

4. Stein M, Rappuoli R, Covacci A. Tyrosine phosphorylation of the Helicobacter pylori
CagA antigen after cag-driven host cell translocation. Proc Natl Acad Sci U S A.
2000;97(3):1263-8.

5. Mejias-Luque R, Zoller J, Anderl F, Loew-Gil E, Vieth M, Adler T, et al. Lymphotoxin beta receptor signalling executes Helicobacter pylori-driven gastric inflammation in a T4SSdependent manner. Gut. 2017;66(8):1369-81.

665 6. Oertli M, Sundquist M, Hitzler I, Engler DB, Arnold IC, Reuter S, et al. DC-derived IL-18 drives Treg differentiation, murine Helicobacter pylori-specific immune tolerance, and 667 asthma protection. J Clin Invest. 2012;122(3):1082-96.

Kaebisch R, Mejias-Luque R, Prinz C, Gerhard M. Helicobacter pylori cytotoxin associated gene A impairs human dendritic cell maturation and function through IL-10 mediated activation of STAT3. J Immunol. 2014;192(1):316-23.

8. Kao JY, Zhang M, Miller MJ, Mills JC, Wang B, Liu M, et al. Helicobacter pylori
immune escape is mediated by dendritic cell-induced Treg skewing and Th17 suppression in
mice. Gastroenterology. 2010;138(3):1046-54.

674 9. Oertli M, Noben M, Engler DB, Semper RP, Reuter S, Maxeiner J, et al. Helicobacter
675 pylori gamma-glutamyl transpeptidase and vacuolating cytotoxin promote gastric persistence
676 and immune tolerance. Proc Natl Acad Sci U S A. 2013;110(8):3047-52.

677 10. Chen CC, Liou JM, Lee YC, Hong TC, El-Omar EM, Wu MS. The interplay between
678 Helicobacter pylori and gastrointestinal microbiota. Gut Microbes. 2021;13(1):1-22.

Lofgren JL, Whary MT, Ge Z, Muthupalani S, Taylor NS, Mobley M, et al. Lack of
 commensal flora in Helicobacter pylori-infected INS-GAS mice reduces gastritis and delays
 intraepithelial neoplasia. Gastroenterology. 2011;140(1):210-20.

682 12. Gravina AG, Zagari RM, De Musis C, Romano L, Loguercio C, Romano M.
683 Helicobacter pylori and extragastric diseases: A review. World J Gastroenterol.
684 2018;24(29):3204-21.

13. Zuo Y, Jing Z, Bie M, Xu C, Hao X, Wang B. Association between Helicobacter pylori
infection and the risk of colorectal cancer: A systematic review and meta-analysis. Medicine
(Baltimore). 2020;99(37):e21832.

Becht E, McInnes L, Healy J, Dutertre CA, Kwok IWH, Ng LG, et al. Dimensionality
 reduction for visualizing single-cell data using UMAP. Nat Biotechnol. 2018.

690 15. Osman A, Yan B, Li Y, Pavelko KD, Quandt J, Saadalla A, et al. TCF-1 controls Treg
691 cell functions that regulate inflammation, CD8(+) T cell cytotoxicity and severity of colon
692 cancer. Nat Immunol. 2021;22(9):1152-62.

Miragaia RJ, Gomes T, Chomka A, Jardine L, Riedel A, Hegazy AN, et al. Single-Cell
 Transcriptomics of Regulatory T Cells Reveals Trajectories of Tissue Adaptation. Immunity.
 2019;50(2):493-504 e7.

Vasanthakumar A, Liao Y, Teh P, Pascutti MF, Oja AE, Garnham AL, et al. The TNF
Receptor Superfamily-NF-kappaB Axis Is Critical to Maintain Effector Regulatory T Cells in
Lymphoid and Non-lymphoid Tissues. Cell Rep. 2017;20(12):2906-20.

La Manno G, Soldatov R, Zeisel A, Braun E, Hochgerner H, Petukhov V, et al. RNA
velocity of single cells. Nature. 2018;560(7719):494-8.

Parikh K, Antanaviciute A, Fawkner-Corbett D, Jagielowicz M, Aulicino A, Lagerholm
C, et al. Colonic epithelial cell diversity in health and inflammatory bowel disease. Nature.
2019;567(7746):49-55.

Moor AE, Harnik Y, Ben-Moshe S, Massasa EE, Rozenberg M, Eilam R, et al. Spatial
 Reconstruction of Single Enterocytes Uncovers Broad Zonation along the Intestinal Villus
 Axis. Cell. 2018;175(4):1156-67 e15.

Protection of proinflammatory responses by the Helicobacter pylori CagA protein. Proc Natl Acad Sci U S A. 2005;102(26):9300-5.

Menheniott TR, Judd LM, Giraud AS. STAT3: a critical component in the response to
 Helicobacter pylori infection. Cell Microbiol. 2015;17(11):1570-82.

Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T, et al.
 gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle
 progression during colitis-associated tumorigenesis. Cancer cell. 2009;15(2):91-102.

- 715 24. Nguyen AV, Wu YY, Liu Q, Wang D, Nguyen S, Loh R, et al. STAT3 in epithelial cells 716 regulates inflammation and tumor progression to malignant state in colon. Neoplasia. 717 2013;15(9):998-1008.
- Asada R, Saito A, Kawasaki N, Kanemoto S, Iwamoto H, Oki M, et al. The
 endoplasmic reticulum stress transducer OASIS is involved in the terminal differentiation of
 goblet cells in the large intestine. J Biol Chem. 2012;287(11):8144-53.

Aden K, Rehman A, Falk-Paulsen M, Secher T, Kuiper J, Tran F, et al. Epithelial IL23R Signaling Licenses Protective IL-22 Responses in Intestinal Inflammation. Cell Rep.
2016;16(8):2208-18.

- 724 27. Katoh M, Katoh M. Notch signaling in gastrointestinal tract (review). Int J Oncol. 725 2007;30(1):247-51.
- Wirbel J, Pyl PT, Kartal E, Zych K, Kashani A, Milanese A, et al. Meta-analysis of
 fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer.
 Nat Med. 2019;25(4):679-89.
- 29. Guo Y, Zhang Y, Gerhard M, Gao JJ, Mejias-Luque R, Zhang L, et al. Effect of Helicobacter pylori on gastrointestinal microbiota: a population-based study in Linqu, a highrisk area of gastric cancer. Gut. 2020;69(9):1598-607.

van Zanten SJ, Kolesnikow T, Leung V, O'Rourke JL, Lee A. Gastric transitional
zones, areas where Helicobacter treatment fails: results of a treatment trial using the Sydney
strain mouse model. Antimicrob Agents Chemother. 2003;47(7):2249-55.

735 31. Franceschi F, Covino M, Roubaud Baudron C. Review: Helicobacter pylori and 736 extragastric diseases. Helicobacter. 2019;24 Suppl 1:e12636.

- 32. Kim TJ, Kim ER, Chang DK, Kim YH, Baek SY, Kim K, et al. Helicobacter pylori
 infection is an independent risk factor of early and advanced colorectal neoplasm.
 Helicobacter. 2017;22(3).
- 33. Arnold IC, Dehzad N, Reuter S, Martin H, Becher B, Taube C, et al. Helicobacter
 pylori infection prevents allergic asthma in mouse models through the induction of regulatory
 T cells. J Clin Invest. 2011;121(8):3088-93.
- 34. Caruso R, Fina D, Paoluzi OA, Del Vecchio Blanco G, Stolfi C, Rizzo A, et al. IL-23mediated regulation of IL-17 production in Helicobacter pylori-infected gastric mucosa. Eur J
 Immunol. 2008;38(2):470-8.

Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, et al. Clinical
impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in
patients with colorectal cancer. Cancer Res. 2011;71(4):1263-71.

- 36. Du R, Zhao H, Yan F, Li H. IL-17+Foxp3+ T cells: an intermediate differentiation stage between Th17 cells and regulatory T cells. J Leukoc Biol. 2014;96(1):39-48.
- 37. Ma C, Dong X. Colorectal cancer-derived Foxp3(+) IL-17(+) T cells suppress tumour specific CD8+ T cells. Scand J Immunol. 2011;74(1):47-51.
- 38. Yang S, Wang B, Guan C, Wu B, Cai C, Wang M, et al. Foxp3+IL-17+ T cells
 promote development of cancer-initiating cells in colorectal cancer. J Leukoc Biol.
 2011;89(1):85-91.

 39. Sinicrope FA, Rego RL, Ansell SM, Knutson KL, Foster NR, Sargent DJ.
 Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology. 2009;137(4):1270-9.

40. Smith G, Carey FA, Beattie J, Wilkie MJ, Lightfoot TJ, Coxhead J, et al. Mutations in
APC, Kirsten-ras, and p53--alternative genetic pathways to colorectal cancer. Proc Natl Acad
Sci U S A. 2002;99(14):9433-8.

Janssen KP, Alberici P, Fsihi H, Gaspar C, Breukel C, Franken P, et al. APC and
 oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and
 progression. Gastroenterology. 2006;131(4):1096-109.

Schwitalla S, Fingerle AA, Cammareri P, Nebelsiek T, Goktuna SI, Ziegler PK, et al.
Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like
properties. Cell. 2013;152(1-2):25-38.

43. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis:
a meta-analysis. Gut. 2001;48(4):526-35.

44. Waldner MJ, Neurath MF. Mechanisms of Immune Signaling in Colitis-Associated
 Cancer. Cell Mol Gastroenterol Hepatol. 2015;1(1):6-16.

45. Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Inoue K, et al. Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. Oncol Rep. 2006;15(6):1445-51.

46. Musteanu M, Blaas L, Mair M, Schlederer M, Bilban M, Tauber S, et al. Stat3 is a
negative regulator of intestinal tumor progression in Apc(Min) mice. Gastroenterology.
2010;138(3):1003-11 e1-5.

47. Li Y, Kundu P, Seow SW, de Matos CT, Aronsson L, Chin KC, et al. Gut microbiota
accelerate tumor growth via c-jun and STAT3 phosphorylation in APCMin/+ mice.
Carcinogenesis. 2012;33(6):1231-8.

48. Compare D, Nardone G. Contribution of gut microbiota to colonic and extracolonic
 cancer development. Dig Dis. 2011;29(6):554-61.

49. Wick EC, Rabizadeh S, Albesiano E, Wu X, Wu S, Chan J, et al. Stat3 activation in
murine colitis induced by enterotoxigenic Bacteroides fragilis. Inflamm Bowel Dis.
2014;20(5):821-34.

Iino C, Shimoyama T. Impact of Helicobacter pylori infection on gut microbiota. World
 J Gastroenterol. 2021;27(37):6224-30.

51. Kienesberger S, Cox LM, Livanos A, Zhang XS, Chung J, Perez-Perez GI, et al.
Gastric Helicobacter pylori Infection Affects Local and Distant Microbial Populations and Host
Responses. Cell reports. 2016;14(6):1395-407.

52. Uronis JM, Muhlbauer M, Herfarth HH, Rubinas TC, Jones GS, Jobin C. Modulation
of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS
One. 2009;4(6):e6026.

53. Wang L, Tang L, Feng Y, Zhao S, Han M, Zhang C, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurised bacterium blunts colitis associated tumourigenesis by modulation of CD8(+) T cells in mice. Gut. 2020;69(11):1988-97.

797 54. Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP. Stool 798 microbiome and metabolome differences between colorectal cancer patients and healthy 799 adults. PLoS One. 2013;8(8):e70803.

55. Jarosch S, Köhlen J, Sarker RSJ, Steiger K, Janssen KP, Christians A, et al.
 Multiplexed imaging and automated signal quantification in formalin-fixed paraffin-embedded
 tissues by ChipCytometry. Cell Reports Methods. 2021;1(7).

803 56. Wolf FA, Angerer P, Theis FJ. SCANPY: large-scale single-cell gene expression data
804 analysis. Genome Biol. 2018;19(1):15.

57. Luecken MD, Theis FJ. Current best practices in single-cell RNA-seq analysis: a tutorial. Mol Syst Biol. 2019;15(6):e8746.

58. Bergen V, Lange M, Peidli S, Wolf FA, Theis FJ. Generalizing RNA velocity to transient cell states through dynamical modeling. Nat Biotechnol. 2020;38(12):1408-14.

809 59. Reitmeier S, Kiessling S, Neuhaus K, Haller D. Comparing Circadian Rhythmicity in 810 the Human Gut Microbiome. STAR Protoc. 2020;1(3):100148.

811 60. Reitmeier S, Kiessling S, Clavel T, List M, Almeida EL, Ghosh TS, et al. Arrhythmic
812 Gut Microbiome Signatures Predict Risk of Type 2 Diabetes. Cell Host Microbe.
813 2020;28(2):258-72 e6.

814 61. Zoetendal EG, Heilig HG, Klaassens ES, Booijink CC, Kleerebezem M, Smidt H, et al.
815 Isolation of DNA from bacterial samples of the human gastrointestinal tract. Nat Protoc.
816 2006;1(2):870-3.

62. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457(7228):480-4.

Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD. Development of a
dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data
on the MiSeq Illumina sequencing platform. Appl Environ Microbiol. 2013;79(17):5112-20.

822 64. Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, et al.
823 Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2.
824 Nat Biotechnol. 2019;37(8):852-7.

825 65. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, et al. 826 Metagenomic biomarker discovery and explanation. Genome Biol. 2011;12(6):R60.

827



Fig. 1: H. pylori promotes intestinal carcinogenesis in Apc mouse models

(A) Kaplan-Meier survival curve comparing *H. pylori* infected and non-infected Apc^{+/min} mice.

(B) Tumor counts of *H. pylori* infected (n=18) and non-infected (n=10) *Apc*^{+/min} mice in small intestine and colon. (C) Representative pictures of tumors (arrows) in the small intestine and colon of *H. pylori* infected and non-

infected (Cont.) Apc^{+/min} mice.

Each symbol represents one animal, from 3 independent, pooled experiments. Bars denote median. Statistical significance was determined with Mann-Whitney-U test or unpaired t-test, *p < 0.05.



Fig. 2: *H. pylori* infection induces a pro-inflammatory response in the intestine

(A) Representative pictures of colonic CD3+ stainings of *H. pylori* infected and non-infected $Apc^{+/min}$ mice after 12 weeks of infection are shown. White scale bars correspond to 200 µm, black scale bars to 20 µm. Quantification of positive cells per mm² small intestine and colon tissue is shown. Pooled data of 3 independent experiments.

(B) Flow cytometric analysis of intestinal lamina propria lymphocytes isolated from *H. pylori* infected and non-infected *Apc*^{+/min} mice after 12 weeks of infection. Frequency of FoxP3+ positive cells of CD4+ T-cells are shown, gated on live, single cells, CD45+ and CD3+. Pooled data of 2 independent experiments.

(C) Representative CD3+ staining of stomach, small intestine and colon tissue sections of *H. pylori* infected and non-infected C57BL/6 mice after 24 weeks of infection. Quantification of intraepithelial cells per mm² is shown. White scale bars correspond to 200 μ m, black scale bars to 20 μ m. Pooled ata of two independent experiments. (D) Frequency of FoxP3 positive cells of CD4+ T-cells are shown. Cells were gated on live, single cells, CD45+ and CD3+. Pooled data of 2 independent experiments.

(E) Overview of colon tissue stained with multiplexed chip cytometry. Automatic image processing of multiplexed chip cytometry on colon tissue determines CD4+ T-cell properties in *H. pylori* positive and negative C57BL/6 mice. Frequencies of conventional T-cells (Tconv), regulatory T-cells (Treg) and intraepithelial regulatory T-cells (IE Treg) are shown. Scale bar in overview corresponds to 500µm. Representative picture of colon tissue stained with multiplexed chip cytometry. FoxP3+ cell, defined by intranuclear FoxP3+, CD4+ CD3+ and CD45+ staining. Large scale bar corresponds to 100µm, small scale bars to 10µm. Representative data of one experiment.

(F) Annotated immune cells plotted as UMAP, clusters for further analysis are highlighted (1=CD4 Treg, 2=CD8 and CD8 TRM).

(G) Unsupervised clustering and annotation of Treg cluster as UMAP, n=217 cells. activated Tregs = act. Tregs, pTregs =peripherally induced Tregs, tTregs = thymically derived Tregs.

(H) Gene set score of Treg effector genes and Th17 differentiation genes, comparing activated Treg cells from small intestine and colon of *H. pylori* infected and non-infected *Apc*^{+/min} (APC) mice. Statistical significance was determined with Kruskal-Wallis test.

Each symbol represents one animal/single cell, pooled from at least 2 independent experiments (n=6-10 mice/group/experiment) or 2 mice/group for single-cell data. Bars denote median. Unless otherwise specified, statistical significance was determined with student's t-test in case of normal distribution, otherwise by Mann-Whitney U test, *p < 0.05, **p < 0.01, ****p < 0.001, ****p < 0.001.



Fig. 3: Activation of carcinogenic signaling pathways and loss of goblet cells characterize the intestinal epithelial response to *H. pylori* infection

(Å) Annotated epithelial cells after unsupervised clustering plotted in UMAP space, n=2 mice per group, n= 4249 cells. Clusters for further analysis are highlighted (1= Enterocytes)

(B) Gene set score of STAT3 signaling genes, comparing intestinal enterocytes from *H. pylori* infected and non-infected $Apc^{+/+}$ (WT) and $Apc^{+/\min}$ (APC) mice. Statistical significance was determined with Kruskal-Wallis test.

(C) Representative pSTAT3, Ki67 and PAS staining of small intestine and colon tissue of *H. pylori*-infected and non-infected C57BL/6 mice. Quantification of positive cells per mm² is shown. White scale bars correspond to 200 µm, black scale bars to 20 µm. Pooled data of 2 independent experiments.

(D) Representative pictures of colonic pSTAT3 staining of *H. pylori* infected and non-infected Apc^{+/min} and Apc^{+/1638N} mice are shown. White scale bars correspond to 200 μ m, black scale bars to 20 μ m. Quantification of positive cells per mm² are shown. Pooled data of 3 independent experiments.

(E) Representative pictures of colonic PAS staining of *H. pylori* infected and non-infected $Apc^{+/min}$ and $Apc^{+/1638N}$ mice are shown. White scale bars correspond to 200 µm, black scale bars to 20 µm. Quantification of positive cells per mm² are shown. Pooled data of 3 independent experiments.

Each symbol represents one animal/single cell, pooled from at least 2 independent experiments (n=6-10 mice/group/experiment) or 2 mice/group for single-cell data. Bars denote median. Unless otherwise specified, statistical significance was determined with student's t-test in case of normal distribution, otherwise by Mann-Whitney U test, *p < 0.05, **p < 0.01, ****p < 0.001, ****p < 0.001.



Fig. 4: H. pylori infection favors the presence of mucus-degrading microbiota

(A) Relative taxonomic frequencies on phyla level in 16S rRNA sequenced caecum and colon samples of *H. pylori* infected and non-infected C57BL/6 mice (n=6-8mice/group).

(B) Feature counts (ASVs) of *Akkermansia spp.* and *Ruminococcus spp.* in ceacum, stool, small intestine and colon of *H. pylori* infected and non-infected C57BL/6 mice (n=6-8mice/group).

(C) Feature counts (ASVs) of *Ruminococcus spp.* of ceacum, stool, small intestine and colon of *H. pylori* infected and non-infected *Apc*^{+/min} mice (n=4-5mice/group).

(D) Feature counts (ASVs) of *Akkermansia spp.* of ceacum, stool, small intestine and colon of *H. pylori* infected and non-infected $Apc^{+/1638N}$ mice (n=4-5mice/group).

Data of one representative experiment of 2-3 independent experiments, shown as bars with mean and standard deviation (SD). Statistical significance was determined with Mann-Whitney U test, *p < 0.01, **p < 0.001.

С Α В Small intestine Small intestine Colon Intestine 41,3 60 1,000 300-400-Cont FoxP3 of CD4+ (%) 800 300 200 200 100 -005 CD3+/mm² 100 CD3+/mm² 600 58.7 400 26,0 200 pyion 0 0 FoxP3 0 Apc+/1638N Apc+/1638N Apc+/1638N Apc* H. pylori -74,0 + H. pylori + H. pylori + H. pylori + CD4 germ-free germ-free germ-free germ-free Ε D F Small intestine Colon 6 400-1,500 Tumor number/animal Tumor number/animal Cont. C 300 PAS/mm² 1,000 4 PAS/mm² 200 Т 500· 2 2 100 pylori 1cm 0 0 0 n Apc+/1638N Apc+/1638N Apc^{+/1638N} Stool Apc^{+/+} Apc^{+/1638N} donor Cont. H. pylori Cont. H. pylori H. pylori + H. pylori -+ H. pylori -+ germ-free germ-free germ-free G Н Cont 6 Control tumor number/animal Apc^{+/1638N} C57BL/6 eradication therapy H. pylori PMSS1 ABX analysis analysis . analysis ABX 🔺 H. pylori Λ Control H. pylori ABX ABX H. pylori 2 → H. pylori + ABX 6 weeks . 4 weeks 12 weeks post eradication 24 weeks post eradication 4 weeks p.i. f. pylori ABX 0 Apc^{+/1638N} 1cm J H. pylori H. pylori + ABX 2,000 H. pylori ABX H. pylori • Control ABX
 H. pylori 13,7 15,1 1.500 CD3⁺/mm² H. pylori ABX CD3+ 1,000 FoxP3 500 86<u>,3</u> 84,9 CD4 0 12 weeks 4 weeks Κ 40 Control
ABX
H. pylori
H. pylori ABX 5. (%) Control
ABX
H. pylori IL-17A of CD4+ (%) H. pylori H. pylori + ABX 30 4-FoxP3 of CD4+ 3,33 0.99 2.41 .35 H. pylori ABX 3-20 2. 10 IL-17A 1 36.0 59,3 38,2 58,4 0 0 4 weeks 12 weeks H.p CD4 12 weeks L H. pylori H. pylori + ABX pSTAT3 4,000 1,000 Control Control p=0.06 ABX ABX 3,000 2,000 2,000 1,000 800 H. pylori H. pylori PAS/mm² H. pylori ABX H. pylori ABX 600 200µm 400-** 🗶 200 PAS 1 0-0 4 weeks 12 weeks 4 weeks 12 weeks

C

medRxiv preprint doi: https://doi.org/10.1101/2022.06.16.22276474; this version posted June 17, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Fig. 5: H. pylori induced intestinal carcinogenesis is prevented by eradication

(A) Quantification of small intestinal and colonic intraepithelial CD3+ cells per mm² of *H. pylori* infected and non-infected germ-free $Apc^{+/1638N}$ mice is shown. Pooled data of two independent experiments (n= 8 mice/group).

(B) Frequencies of FoxP3+ cells of CD4+ T-cells, gated on live, single cells, CD45+ and CD3+ of *H. pylori* infected and non-infected germ-free $Apc^{+/1638N}$ mice are included. Representative pseudocolor plots are shown. Pooled data of two independent experiments (n= 8 mice/group).

(C) Quantification of intestinal intraepithelial pSTAT3+ cells per mm² of *H. pylori* infected and non-infected germ-free $Apc^{+/1638N}$ mice is shown. Pooled data of two independent experiments (n= 8 mice/group).

(D) Quantification of intestinal and colonic PAS+ cells per mm² of *H. pylori* infected and non-infected germ-free $Apc^{+/1638N}$ mice is shown. Pooled data of two independent experiments (n= 8 mice/group).

(E) Intestinal tumor counts of *H. pylori* infected and non-infected germ-free *Apc*^{+/7638N} mice and representative pictures of tumors (circled) are shown (n=8 mice/group).

(F) Intestinal tumor counts of stool transfer experiments from non-infected and *H. pylori* infected $Apc^{+/+}$ or $Apc^{+/1638N}$ mice, respectively, (stool donors) into germ-free $Apc^{+/1638N}$ mice (stool recipients) are shown. Data of one experiment (n=2-4 mice/group).

(G) Experimental setup of *H. pylori* eradication therapy of C57BL/6 and Apc^{+/1638N} mice.

(H) Tumor counts of non-infected, antibiotically treated, *H. pylori* infected and *H. pylori* eradicated $Apc^{+/1638N}$ mice and representative pictures of tumors in the small intestine. Data of one experiment (n= 2-3 mice/group).

(I) Representative pictures of CD3+ stainings from small intestinal tissue of *H. pylori* infected and eradicated C57BL/6 mice are shown. White scale bars correspond to 200 μ m, black scale bars to 20 μ m. Quantification of positive cells per mm² is shown. Data of one experiment (n= 5-6 mice/group).

(J) Flow cytometric analysis of intestinal lamina propria lymphocytes reveals frequency of FoxP3+ CD4+ T-cells, gated

on live, single cells, CD45+ and CD3+. Data of one experiment (n= 5-6 mice/group).

(K) Flow cytometric analysis of intestinal lamina propria lymphocytes reveals IL-17A release of CD4+ T-cells, restimulated with whole *H. pylori* lysate. Cells are gated on live, single cells, CD45+ and CD3+. Data of one experiment (n= 5-6 mice/group).

(L) Representative pictures of pSTAT3 and PAS staining from intestinal tissue of H. pylori infected and eradicated C57BL/6 mice are shown. White scale bars correspond to 200 μ m, black scale bars to 20 μ m. Quantification of positive cells per mm² is shown. Data of one experiment (n= 5-6 mice/group).

Each symbol represents one animal. Bars denote median. Statistical significance between two groups was determined with student's t-test in case of normal distribution and otherwise with Mann-Whitney U test. Among more than 2 groups, ordinary one-way ANOVA with Tukey's multiple comparisons test was applied in case of normal distribution, otherwise Kruskal-Wallis-Test with Dunn's multiple comparisons test, *p < 0.05, **p < 0.01, ****p < 0.001, ****p < 0.001.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.16.22276474; this version posted June 17, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Fig. 6: H. pylori alters colonic homeostasis in human

(A) Representative HE, CD3+, pSTAT3 and PAS pictures of colonic tissue from *H. pylori* currently infected, eradicated and non-infected patients are shown. White scale bars correspond to 200 μm, black scale bars to 20 μm. Quantification of total CD3+, intraepithelial STAT3 and PAS positive cells per mm² are shown.

(B) Representative pictures of human colon tissue stained by multiplexed chip cytometry. FoxP3+ cell, defined by intranuclear FoxP3+, CD4+, CD3+ and CD45+ staining are shown for *H. pylori* negative and positive tissue. Large scale bar corresponds to 100µm, small scale bar to 10µm. Automatic image processing of multiplexed chip cytometry on colon tissue determines CD4+ T-cell properties in *H. pylori* positive and negative individuals: frequencies of conventional T-cells (Tconv), regulatory T-cells (Treg) and intraepithelial regulatory T-cells (IE Treg) are shown.

(C) Flow cytometric analysis of colon biopsies from *H. pylori* currently infected, eradicated and non-infected patients were conducted. Frequencies of FoxP3+ cells of CD4+ T-cells, gated on live, single cells, CD45+ and CD3+ are shown and representative pseudocolor plots of *H. pylori* currently infected and negative individuals are included.

(D) Bray-Curtis dissimilarity depicting beta-diversity between *H. pylori* infected and eradicated as well as *H. pylori* infected and non-infected patients. Statistical significance was determined with PERMANOVA. Each symbol represents one patient, shown as bars with mean and standard deviation (SD). Statistical significance was determined with ordinary one-way ANOVA with Tukey's multiple comparisons test in case of normal distribution, otherwise by Kruskal-Wallis-Test with Dunn's multiple comparisons test. *p < 0.05, **p < 0.01, ***p < 0.001.



Fig. S1:

(A) Experimental setup for infection of $Apc^{+/\min}$ and $Apc^{+/1638N}$ mice.

(B) Colony forming units (CFU) per milligram (mg) stomach tissue of *H. pylori* infected $Apc^{+/\min}$ mice after 12 weeks of infection and $Apc^{+/1638N}$ mice after 24 weeks of infection.

(C) Tumor counts of *H. pylori* infected (n=10) and non-infected (n=8) $Apc^{+/1638N}$ mice after 24 weeks of infection in small intestine and colon. Representative pictures showing tumors (circle) of non-infected (Cont.) and infected (*H. pylori*) mice.

Each symbol represents one animal, from 2-3 independent, pooled experiments. Bars denote median. Statistical significance was determined with Mann-Whitney-U test or unpaired t-test, *p < 0.05.



Fig. S2:

(A) Overantification of OD3+ cells/bei 1910 Small in testing a los celentissted is shown of OD3+ cells and a preprint infected which was set celled by peer raview is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The cells and a preprint of the preprint in perpetuity.

(B) Gating strategy of intestinal lymphocytes. Preliminary lymphocyte gate was applied based on known size and granularity on forward and sideward scatter, followed by exclusion of doublets and dead cells. Afterwards, CD45+ lymphocytes and CD3+ T-cells were selected and subsequent gating was performed on CD4+ or CD8+ T-cells. (C) Frequencies of intraepithelial T-cells detected by flow cytometry in small small intestine and colon of *H. pylori* infected and non-infected *Apc*^{+/min} mice, gated on live, single cells and CD45+. Representative contour plots are included. Data of one representative experiment of 3 independent experiments is shown.

(D) Frequencies of T-cell subtypes detected by flow cytometry of *H. pylori* infected and non-infected *Apc*^{+/min} mice, gated on live, single cells, CD45+ and CD3+. Representative pseudocolor plots are included. Pooled data of two independent experiments are shown.

(E) Mean fluorescence intensity (MFI) of FoxP3+ CD4+ T-cells detected by flow cytometry of *H. pylori* infected and non-infected *Apc*^{+/min} mice, gated on live, single cells, CD45+, CD3+ and CD4+. Data of one representative experiment of 3 independent experiments is shown.

(F) Colony forming units (CFU) in homogenized stomach tissue of *H. pylori* infected C57BL/6 mice after 24 weeks of infection. Pooled data of 2 independent experiments are shown.

(G) Fold change in Foxp3 mRNA expression in stomach, small intestine and colon tissue homogenates, normalized to Gapdh and non-infected control mice ($2-\Delta\Delta$ CT value). Pooled data of 2 independent experiments. (H) Flow cytometric analysis of intestinal lamina propria lymphocytes isolated from *H. pylori* infected and non-infected *Apc^{+/min}* mice. Paired frequency of IL-17A positive cells of CD4+ T-cells (non-stimulated vs. stimulated with whole *H. pylori* lysate) gated on live, single cells, CD45+ and CD3+, and representative pseudocolor plots of IL-17 releasing CD4+ T-cells are shown. Data of one representative experiment of 2 independent experiments is shown.

(I) Experimental setup of single-cell RNA sequencing of CD45+ and EPCAM+ cells isolated from small intestine and colon of *H. pylori* infected and non-infected $Apc^{+/min}$ mice and $Apc^{+/+}$ mice. 2 mice per group were pooled into one sample.

(J) Unsupervised clustering of immune cells plotted as uniform manifold approximation and projection (UMAP), n=2 mice per group, n= 11407 cells. Leiden clustering and annotated clusters for non-infected and infected mice are shown.

(K) Gene matrix of marker genes used for annotation of CD45+ clusters.

(L) Gene matrix of marker genes used for annotation of Treg subclusters.

(M) RNA velocity analysis plotted as UMAP for single CD3+ T cells from non-infected (left) and *H. pylori* infected $Apc^{+/\min}$ mice (right). The directional flow of the velocity arrows between cell clusters shows the projection from the observed state to the predicted future state. Zoom into CD4 Treg RNA velocity analysis of *H. pylori* infected and non infected $Apc^{+/\min}$ mice

Each symbol represents one animal/single cell, pooled from at least 2 independent experiments (n=6-10 mice/group/experiment) or 2 mice/group for single-cell data. Bars denote median. Unless otherwise specified, statistical significance was determined with student's t-test in case of normal distribution, otherwise by Mann-Whitney U test, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.



Tuft cells

eroendocrine cells



В

(A) Unstrapervised cluster in or cepithelist cells dotted es function of the analysis of the a

are shown. Clusters for further analysis are highlighted (1= Stem Cells, 2=Enterocytes, 3= goblet cells).

(B) Gene matrix of marker genes used for annotation of EPCAM+ clusters.

(C) Pseudo-spatial distribution of stem-cell, enterocyte and tumor cell clusters along the crypt villus axis in small intestine and colon of $Apc^{+/+}$ (WT) and $Apc^{+/\min}$ (APC) mice.

(D) Gene set score of STAT3 signaling genes, comparing intestinal stem cells from *H. pylori* infected and non-infected $Apc^{+/+}$ (WT) and $Apc^{+/\min}$ (APC) mice.

(E) Gene set score of NFkB signaling genes, comparing intestinal enterocytes from *H. pylori* infected and non-infected $Apc^{+/+}$ (WT) and $Apc^{+/\min}$ (APC) mice.

(F) Unsupervised clustering and reannotation of goblet cluster plotted as UMAP, n=218 cells.

(G) Gene matrix of marker genes used for annotation of goblet cell subclusters.

(H) Relative frequency of goblet subtypes in $Apc^{+/+}$ (WT) and $Apc^{+/\min}$ (APC) mice, grouped by infection.

(I) Gene set score of antimicrobial peptide genes, comparing immature goblet cells of small intestine from *H. pylori* infected and non-infected $Apc^{+/+}$ (WT) and $Apc^{+/\min}$ (APC) mice.

(J) RNA velocity analysis plotted as UMAP for single EPCAM+ cells from non-infected and *H. pylori* infected mice in small intestine and colon. The directional flow of the velocity arrows between cell clusters shows the projection from the observed state to the predicted future state. Squares highlight and zoom in to goblet, paneth cell and coloncytes clusters from non-infected (=1) and infected (=2) colonic epithelial cells.

(K) Expression of goblet cell differentiation marker Atoh1 in Colon Stem cells and small intestinal Stem cells, comparing *H. pylori* infected and non-infected mice.

Each symbol represents one single-cell, pooled from 2 mice/group. Bars denote median. Statistical significance was determined with Kruskal-Wallis test, *p < 0.05, **p < 0.01, ***p < 0.001.



Fig. S4:

(A) Feature counts (ASVs) of *Helicobacter spp.* in stomach of *H. pylori* infected and non-infected C57BL/6 mice (n=6-8mice/group). Data of one representative experiment of 2 independent experiments. Shown as bars with mean and standard deviation (SD). Statistical significance was determined with Mann-Whitney U test, **p < 0.01. (B) Shannon index depicting alpha-diversity in ceacum, stool, small intestine and colon of *H. pylori* infected and non-infected C57BL/6 mice (n=6-8mice/group). Data of one representative experiment of 2 independent experiments. Shown as box and whiskers with (SD). Statistical significance was determined with Mann-Whitney U test, **p < 0.01. (b) Shannon index depicting alpha-diversity in ceacum, stool, small intestine and colon of *H. pylori* infected and non-infected C57BL/6 mice (n=6-8mice/group). Data of one representative experiment of 2 independent experiments. Shown as box and whiskers with (SD). Statistical significance was determined with Mann-Whitney U test, **p < 0.01.

(C) Bray-Curtis dissimilarity depicting beta-diversity of ceacum, stool, small intestine and colon between *H. pylori* infected and non-infected C57BL/6 mice (n=6-8mice/group). Data of one representative experiment of 2 independent experiments. Statistical significance was determined with PERMANOVA. (D) Linear discriminant effect size analysis (LEfSe) determining differentially abundant features of caecum, stool, small intestine and colon tissue upon *H. pylori* infection of C57BL/6 mice.



Fig. S5:

(A) Experimental setup for infection of gerna free 4297⁶¹⁹³⁸, this version posted June 17, 2022. The copyright holder for this preprint (B) Colony forming units (CFC) per mail strategy of the author/junder, who has granted medRxiv a license to display the preprint integent to the preprint integent of the period of the preprint integent of the preprint integent of the period of the preprint integent of the preprint integent of the preprint integent of the preprint integent of the period of the preprint integent of

(C) Experimental setup for stool transfer from specific-pathogen free mice (non-infected and *H. pylori* infected $Apc^{+/1638N}$ mice, respectively, (stool donors)) to germ-free $Apc^{+/1638N}$ mice (stool recipients).

(D) Representative pictures of CD3+, pSTAT3 and PAS stainings from small intestine and colon of non-infected and *H. pylori* germ-free $Apc^{+/1638N}$ mice are shown. White scale bars correspond to 300 µm in case of small intestine and 200 µm in case of colon, black scale bars to 20 µm.

(E) CFU per mg stomach tissue of *H. pylori* infected and eradicated C57BL/6 and *Apc*^{+/1638N} mice is shown. Data of one experiment (n=3-6 mice/group).

(F) Representative pictures of gastric CD3+ staining and quantification of positive intraepithelial cells per mm² of *H. pylori* infected and eradicated C57BL/6 mice are shown. White scale bars correspond to 200 μ m, black scale bars to 20 μ m. Data of one experiment (n= 5-6 mice/group).

(G) Representative pictures of colonic CD3+, pSTAT3 and PAS stainings from H. pylori infected and eradicated C57BL/6 mice are shown. White scale bars correspond to 200 μ m, black scale bars to 20 μ m. Quantification of positive cells per mm² is shown. Data of one experiment (n= 5-6 mice/group).

Each symbol represents one animal. Bars denote median. Statistical significance was determined with ordinary one- way ANOVA with Tukey's multiple comparisons test in case of normal distribution, otherwise by Kruskal-Wallis-Test with Dunn's multiple comparisons test, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.



Fig. S6:

(A) Flow cytometric analysis of colon biopsies from *H. pylori* currently infected, eradicated and non-infected patients were conducted. Frequencies of CD3+ T-cells, gated on live, single cells, CD45+ and CD3+ are shown and representative contour plots of *H. pylori* currently infected and negative individuals are included.

(B) Frequencies of T-cell subsets CD4 and CD8, gated on live, single cells, CD45+ and CD3+ are shown and representative pseudocolor plots of *H. pylori* currently infected and negative individuals are included.

(C) Overview of colon tissue stained with multiplexed chip cytometry. Automatic image processing of multiplexed chip cytometry on human colon tissue determines CD45+, CD3+, CD4+ and FoxP3+ cells and their location. Large scale bar corresponds to 500µm.

(D) Shannon index as indicator of alpha-diversity of stool samples from *H. pylori* currently infected, eradicated and non-infected individuals are shown. Data shown as box and whiskers with SD.

(E) Ratio of the phyla Firmicutes to Bacteroidetes, shown as bars with mean and SD.

(F) Linear discriminant effect size analysis (LEfSe) determining differentially abundant features of stool samples from *H. pylori* negative and positive individuals. Interesting features are highlighted in black.

(G) Feature counts of Prevotella spp. of stool samples *H. pylori* currently infected, eradicated and non-infected individuals, shown as bars with mean and SD.

Each symbol represents one patient. Statistical significance was determined with ordinary one-way ANOVA with Tukey's multiple comparisons test in case of normal distribution, otherwise by Kruskal-Wallis-Test with Dunn's multiple comparisons test.